- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04580147
Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair (PREVENT-PVR)
A Multi-Center, Randomized, Sham-Controlled, Phase II Trial Evaluating Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Macula Off Rhegmatogenous Retinal Detachment Repair (The PREVENT-PVR Trial)
Study Overview
Status
Intervention / Treatment
Detailed Description
The objective of this study is to determine if serial intravitreal aflibercept injections (IAI) improve single surgery anatomic success rate and reduce development of clinically apparent proliferative vitreoretinopathy (PVR) following surgical repair of primary, macula involving rhegmatogenous retinal detachment (RRD).
This will be a randomized clinical trial, with participant enrollment lasting ~120 days. 150 eyes will be randomized 1:1 to intervention (serial IAI) versus sham control (standard of care). Adult eyes with macula involving primary RRD deemed at high risk for PVR development as determined by pre-specified clinical features are eligible for enrollment.
The study, Aflibercept group will receive intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (plus/minus 7 days), and at post-operative day 60 (plus/minus 7 days). Patients enrolled in the control group will undergo a sham procedure at post-operative day 30 (plus/minus 7 days) and at post-operative day 60 (plus/minus 7 days).
The primary outcome will be single surgery anatomic success (retinal re-attachment) rate. Additional outcomes will include: systemic and ocular safety of IAI in setting of RRD; epiretinal membrane formation; presence of grade C PVR or worse; post-operative complication profile; OCT-measured central macular thickness; change from baseline in visual acuity (Snellen) wearing habitual correction.
All eyes will undergo pars plana vitrectomy with or without scleral buckling and gas tamponade. Post-operative exams (slit lamp biomicroscopy and indirect ophthalmoscopy) will include the following time-points: Day 30, Day 60, Day 90, Day 120. All time points will have a window of plus/minus 7 days, except the Day 120 visit which will be a window of plus/minus 14 days.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Brianna Kenney
- Phone Number: 215-928-3092
- Email: research@midatlanticretina.com
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Wills Eye Hospital
-
Contact:
- Brianna Kenney
- Phone Number: 215-928-3092
- Email: research@midatlanticretina.com
-
Principal Investigator:
- Mohammed A Khan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Carry a diagnosis of a macula involving ("macula off") primary RRD at high risk for PVR development. Specifically, the enrolled eye must include at least 1 but no more than 3 high risk features, which are designated as follows: multiple retinal breaks (>3); detachments involving two or more quadrants of the retina; duration of detachment > 3 weeks; vitreous hemorrhage; and choroidal detachment.
- Consent to surgical repair utilizing pars plana vitrectomy with or without scleral buckling and C3F8 gas tamponade
- Willing and able to comply with clinic visits and study-related procedures
- Provide signed informed consent
- Able to understand and complete study-related questionnaires
Exclusion Criteria:
- Age <18 years
- Presence of PVR grade B or worse (as defined by the revised Retina Society PVR classification system) at time of surgical repair
- Method of primary RRD repair is primary laser demarcation, primary cryotherapy, pneumatic retinopexy, or scleral buckling procedure alone.
- Primary use of silicone oil or retinectomy during surgical repair (if silicone oil and/or a retinectomy is used intraoperatively, a prior enrolled patient will be disqualified from the study)
- Prior incisional ocular surgery other than cataract extraction
- History of or concurrent ruptured globe, intraocular foreign body, diabetic retinopathy, retinal vein occlusion, exudative age-related macular degeneration, macular hole, epiretinal membrane, sickle cell disease, uveitis or intraocular infectious disease
- Treatment with intravitreal or systemic anti-VEGF pharmacotherapy in the prior 6 months.
- Pregnant or breastfeeding women
- Sexually active women of childbearing potential* who are unwilling to practice adequate contraception prior to start of the first treatment, during the study, and for at least 3 months after the last dose. Adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention (serial IAI)
Intravitreal aflibercept injection (2mg/0.05mL)
at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
|
Intravitreal aflibercept injection (2mg/0.05mL)
at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
Other Names:
|
Sham Comparator: Control
Patients enrolled in the control group will undergo a sham procedure at post-operative day 30 (+/-7 days) and at post-operative day 60 (+/-7 days)
|
Sham procedure at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Single surgery anatomic success (retinal re-attachment) rate
Time Frame: 4 months
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed on ophthalmic examination at all time points
Time Frame: 4 months
|
Adverse events of interest include endophthalmitis, intraocular inflammation, or retinal tear/detachment.
|
4 months
|
The number of participants with an epiretinal membrane as assessed on ocular examination or optical coherence tomography imaging
Time Frame: 4 months
|
Epiretinal membrane is defined as preretinal membrane overlying the macula.
|
4 months
|
The number of participants with evidence of grade C proliferative vitreoretinopathy (PVR) on retinal examination. Presence of grade C PVR or worse
Time Frame: 4 months
|
PVR Grade C is defined by preretinal or subretinal retinal membrane, including a retinal star fold
|
4 months
|
Change from baseline in visual acuity (Snellen) wearing habitual correction.
Time Frame: 4 months
|
Visual acuity will be measured using a typical Snellen chart.
|
4 months
|
OCT-measured central subfield thickness
Time Frame: 4 months
|
Automated or manual central subfield thickness will be measured using the optical coherence tomography software.
|
4 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mohammed A Khan, M, Wills Eye Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PREVENTPVR_V1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Proliferative Vitreoretinopathy
-
Shahid Beheshti University of Medical SciencesUnknownProliferative VitreoretinopathyIran, Islamic Republic of
-
Shahid Beheshti University of Medical SciencesCompletedProliferative VitreoretinopathyIran, Islamic Republic of
-
Stanford UniversityWithdrawnProliferative VitreoretinopathyUnited States
-
Centro Oftalmológico Dr CharlesCompletedProliferative VitreoretinopathyArgentina
-
National Eye Institute (NEI)CompletedRetinal Detachment | Proliferative Vitreoretinopathy
-
Shahid Beheshti University of Medical SciencesUnknownProliferative VitreoretinopathyIran, Islamic Republic of
-
Wills EyeCompletedProliferative VitreoretinopathyUnited States
-
University of Health Sciences LahoreRecruitingProliferative VitreoretinopathyPakistan
-
Shanghai 10th People's HospitalUnknown
Clinical Trials on Intravitreal aflibercept injection
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Innovent Biologics (Suzhou) Co. Ltd.SuspendedDiabetic Macular Edema | Neovascular Age-related Macular DegenerationChina
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Germany, Hong Kong, Lithuania, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
-
Kim's Eye HospitalBayerRecruitingRetinal Angiomatous ProliferationKorea, Republic of
-
Instituto de Olhos de GoianiaUnknownChoroidal Retinal NeovascularizationBrazil
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Regeneron PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Regeneron PharmaceuticalsBayerCompleted
-
Regeneron PharmaceuticalsCompletedNonproliferative Diabetic RetinopathyUnited States, Germany, Hungary, Japan, Puerto Rico, United Kingdom